Zetta Genomics

Genome-optimized data for precision medicine

Cambridge, United Kingdom

Zetta Genomics is a genomics company spun out from University of Cambridge and Genomics England in 2017, headquartered in Cambridge, UK with offices in Valencia, Spain. It specializes in managing genomes.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Zetta Genomics on @MedStartr Today Zetta Genomics is a genomics company spun out from University of Cambridge and Genomics England in 2017, headquartered in Cambridge, UK with offices in Valencia, Spain. It specializes in managing genomes. #RareDiseases #PrecisionMedicine #CancerOncology #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/mv8jXWLyA0E

Get Involved in Zetta Genomics

How We Help

Problem Statement

The company solves the problem of managing and analyzing large, complex genomic datasets, which traditionally hinder the scalability and real-time application of precision medicine, discovery, and diagnosis.

Core Technology

Genomics data management platform

Key Differentiators

Specializes in managing genomes

Clinical Focus

Precision Medicine; Diagnostics; Therapeutics; Healthcare Analytics; Population Research

Company Info

Business Model: SaaS
Founded: 2018
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: zettagenomics.com/

Disease Areas

Rare Diseases Precision Medicine Cancer & Oncology

Technologies

GenomicsData Management

Clinical & IP

🔬

Clinical Validation

ISO compliance and robust Quality Management System with IVD regulatory compliance. Deployed in NHS and clinical labs. Indexed 150k+ genomes in clinical and research settings.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Zetta Genomics?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.